openPR Logo
Press release

Anti-viral Therapeutics Market Forecast 2025 | Discover Next-Gen Antivirals & Biopharma Innovations

08-05-2025 03:14 PM CET | Health & Medicine

Press release from: DataM Intelligence 4Market Research LLP

Anti-viral Therapeutics Market

Anti-viral Therapeutics Market

The Anti-Viral Therapeutics Market size was valued US$ 51.72 billion in 2021 and is estimated to reach US$70.83 billion by 2031, growing at a CAGR of 4.6% during the forecast period (2024-2031), according to DataM Intelligence. This growth is fuelled by rising demand for effective antiviral drugs, advancements in drug development technologies, and enhanced screening and diagnostic capabilities, enabling earlier detection and treatment initiation. Leading pharmaceutical companies include Gilead Sciences, Johnson & Johnson, Merck & Co., AbbVie, Bristol-Myers Squibb, Roche, Pfizer, GlaxoSmithKline, and Moderna.

Download your FREE sample report: https://www.datamintelligence.com/download-sample/anti-viral-therapeutics-market?jd

Emerging opportunities lie in the development of next-generation antivirals, including direct-acting antivirals (DAAs), RNA interference (RNAi) therapeutics, and host-targeting agents, as well as advances in biologics such as monoclonal antibodies and immunomodulators. The integration of artificial intelligence and machine learning in drug discovery and personalized antiviral regimens further drives innovation. The growth of digital health tools for patient monitoring and adherence is also enhancing therapeutic outcomes.

Influential Strategic Collaborations and Acquisitions Redefining the Anti-Viral Therapeutics Market Dynamics in 2025

1. In July 2025, Island Pharmaceuticals acquired the Galidesivir antiviral program from BioCryst Pharmaceuticals: Island fast-tracked this asset purchase agreement following due diligence for Galidesivir, a broad-spectrum antiviral effective against multiple RNA viruses, including Ebola, Marburg, MERS, and Zika. The acquisition positions Island strongly in high-priority viral threats with potential FDA approval under the Animal Rule, offering priority review vouchers valued up to $100-150 million.

2. SymBio Pharmaceuticals' portfolio expansion with brincidofovir acquisition: SymBio expanded its antiviral portfolio with rights to brincidofovir (BCV), an oral antiviral with applications against DNA viruses, demonstrating positive proof of concept in recent clinical studies. This strategic move reinforces its position in rare and difficult-to-treat viral infections.

3. Atea Pharmaceuticals advancing oral antiviral therapies: Atea, focused on oral treatments for viral diseases including COVID-19 and influenza, continues clinical development and strategic collaborations across antiviral drug candidates, increasing its pipeline and addressing unmet needs in antiviral therapeutics.

Innovative Technological Advances Driving Transformation in the Anti-Viral Therapeutics Sector in 2025

• Broad-Spectrum Antivirals and Combination Therapies: Drugs like Remdesivir, Molnupiravir, and Paxlovid (nirmatrelvir/ritonavir) became frontline treatments for SARS-CoV-2 and demonstrated the value of combination therapies targeting viral proteases and polymerases. Protease inhibitors such as Simeprevir and Paritaprevir also show antiviral activity beyond their original hepatitis C indications.

• Monoclonal Antibodies and Immunomodulators: Combinations of monoclonal antibodies (bamlanivimab/etesevimab, casirivimab/imdevimab) enhance neutralizing activity against viral variants. IL-6 inhibitors (tocilizumab, sarilumab) and Janus kinase inhibitors (baricitinib, tofacitinib) are utilized to reduce severe COVID-19 inflammation, indicating synergy between antivirals and immunomodulation.

• RNA Interference (RNAi) and Gene Editing: siRNAs and antisense oligonucleotides targeting viral genomes show promise for infections like HBV, HCV, HIV, and herpesviruses by interrupting viral replication and modulating host immune responses.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=anti-viral-therapeutics-market?jd

Prominent Regional Factors Propelling Growth Trends in the Anti-Viral Therapeutics Market by 2025

North America leads the antiviral therapeutics market with the largest share, driven by advanced healthcare infrastructure, high healthcare expenditure, widespread access to medical care, and significant investments in research and development. The U.S. has a high prevalence of viral infections such as HIV, hepatitis B and C, and influenza, fueling demand for innovative antiviral drugs including direct-acting antivirals (DAAs), protease inhibitors, and new molecules targeting emerging viruses.

Europe holds a substantial market share supported by mature healthcare systems, stringent regulatory standards, and active R&D collaborations. Countries like Germany, France, and the UK focus on tackling chronic viral infections and epidemic preparedness by advancing antiviral drug development and expanding treatment access.

Asia Pacific is the fastest-growing regional market fueled by large patient populations, rising prevalence of viral infections, expanding healthcare infrastructure, and increasing availability of generic antivirals. Countries such as China, India, Japan, and South Korea actively enhance healthcare access and invest in biopharma manufacturing capabilities.

Latin America and the Middle East & Africa represent emerging markets with growing prevalence of viral diseases such as HIV/AIDS, hepatitis, and respiratory viruses, coupled with improving healthcare infrastructure and increased government initiatives targeting viral infection control.

Request for 2 Days FREE Access:
https://www.datamintelligence.com/reports-subscription?jd

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drug Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg?jd

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us:

DataM Intelligence is a leading Market Research and Consulting firm offering end-to-end business solutions from research to strategic consulting. At DataM Intelligence, we harness proprietary trends, insights, and industry developments to deliver swift, insightful solutions tailored to your business needs. Our extensive portfolio includes a wide range of syndicated and customized reports, built on a robust research methodology. With a database of over 6,300 reports across 40+ industries, we provide deep statistical analysis and market intelligence that supports the strategic growth of more than 200 companies in over 50 countries, addressing the critical research demands that shape their success.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Anti-viral Therapeutics Market Forecast 2025 | Discover Next-Gen Antivirals & Biopharma Innovations here

News-ID: 4133893 • Views:

More Releases from DataM Intelligence 4Market Research LLP

Taiwan Probiotic Food Market Outlook 2024-2027: Clean-Label, Organic, and Functional Nutrition on the Rise | Quan Jiurong Enterprise Co., Ltd. (Chyuan Jeou Rong Enterprise Co. Ltd.), Kai Kombucha, King Kung Health Food Co., Ltd.
Taiwan Probiotic Food Market Outlook 2024-2027: Clean-Label, Organic, and Functi …
The Taiwan Probiotic Food Market recorded a value of US$ 498.55 million in 2023 and is expected to reach a value of US$ 620.04 million in 2027, growing at a CAGR of 5.72% during the forecast period (2024-2027). Taiwan's Probiotic Food Market includes fermented products and functional foods with live beneficial microorganisms. Growth is driven by digestive health awareness, immunity-boosting trends, and aging population needs. Products include yogurt, kefir, and dietary
Germany Medical Technology market reached US$ 42.2 billion in 2023 and is expected to reach US$ 62.63 billion by 2031 | Siemens Healthineers AG, Carl Zeiss Meditec AG, B. Braun SE
Germany Medical Technology market reached US$ 42.2 billion in 2023 and is expect …
The Germany Medical Technology market reached US$ 42.2 billion in 2023 and is expected to reach US$ 62.63 billion by 2031, growing at a CAGR of 5.1% during the forecast period 2024-2031. Germany's Medical Technology Market encompasses devices, diagnostic equipment, and digital health solutions. Growth is driven by aging populations, chronic disease prevalence, and healthcare innovation. Hospitals, clinics, and research centers are major end-users. Innovations focus on minimally invasive devices, AI
Biopesticides Market Projected to Reach US$24.16B by 2032, Growing at a CAGR of 15.3% on Rising Demand for Eco-Friendly Crop Protection
Biopesticides Market Projected to Reach US$24.16B by 2032, Growing at a CAGR of …
The Biopesticides Market was valued at US$ 7,734.43 million in 2024 and is projected to reach US$ 24,158.10 million by 2032, registering a CAGR of 15.3% during the forecast period 2025-2032. The market focuses on the development and use of biological pest control solutions derived from natural organisms, including microorganisms, plant extracts, and bioactive compounds. Biopesticides are widely applied in agriculture, horticulture, and forestry to control pests, enhance crop protection, and
Japan Wearable Devices Market to Hit $12.31 Billion by 2033, Growing at 12.6% CAGR | Expanding Opportunities in Health, Fitness, and IoT
Japan Wearable Devices Market to Hit $12.31 Billion by 2033, Growing at 12.6% CA …
The Japan wearable devices market reached US$4,026.98 million in 2024 and is expected to reach US$12,310.52 million by 2033, growing at a CAGR of 12.6 % during the forecast period 2025-2033, according to DataM intelligence. Japan's Wearable Devices Market includes smartwatches, fitness trackers, health monitors, and AR/VR devices. Growth is driven by healthcare monitoring, fitness trends, and IoT adoption. Applications span personal wellness, remote patient monitoring, and industrial safety. Companies and

All 5 Releases


More Releases for Therapeutics

Adrenomyeloneuropathy Market: Epidemiology, Therapies, Companies, DelveInsight | …
Adrenomyeloneuropathy emerging therapies are expected to boost the Adrenomyeloneuropathy Market in the upcoming years. DelveInsight has launched a new report on "Adrenomyeloneuropathy - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Adrenomyeloneuropathy, historical and forecasted epidemiology as well as the Adrenomyeloneuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Discover about the Adrenomyeloneuropathy market report @ https://www.delveinsight.com/report-store/adrenomyeloneuropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr Some of the
Pompe Disease Market: Epidemiology, Therapies, Companies, DelveInsight | Genzyme …
Pompe Disease emerging therapies, such as MYOZYME (alglucosidase alfa), LUMIZYME, AAV2/8-LSPhGAA, Avalglucosidase alfa, and others, are expected to boost the Pompe Disease Market in the upcoming years. DelveInsight has launched a new report on "Pompe Disease - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Pompe Disease, historical and forecasted epidemiology as well as the Pompe Disease market trends in the United States, EU5 (Germany, Spain,
Dark Genome Therapeutics Market Deep Research Report with Forecast to 2032 | myN …
The qualitative latest Research report (2025-2032) on the Dark Genome Therapeutics Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves. Request a Sample Copy: https://www.coherentmarketresearch.com/samplepages/133611 Focused on growth
Hodgkin's lymphoma Therapeutics Market Size Report 2032 | Affimed Therapeutics, …
DelveInsight's "Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Hodgkin's Lymphoma, historical and forecasted epidemiology as well as the Hodgkin's Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United kingdom and Japan. Discover Key Insights into the Hodgkin's lymphoma Market with DelveInsight's In-Depth Report @ Hodgkin's lymphoma Market Size- https://www.delveinsight.com/sample-request/hodgkins-lymphoma-hl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways from the Hodgkin's
CRISPR Therapies Pipeline 2024 | Intellia Therapeutics, CRISPR therapeutics, Rep …
DelveInsight's, "CRISPR Therapies Pipeline Insight 2024" report provides comprehensive insights about 25+ CRISPR Therapies Companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the CRISPR Therapies pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CRISPR Therapies therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive CRISPR Therapies pipeline products in this space. Key Takeaways from
Digital Therapeutics Market, Digital Therapeutics Market Size, Digital Therapeut …
The global digital therapeutics market is expected to reach US$ 8,941.1 Mn by 2025 from US$ 1,993.2 Mn in 2017. The market is estimated to grow with a CAGR of 20.8% during the forecast period from 2018 to 2025. North America is the largest geographic market and it is expected to be the largest revenue generator during the forecast period, whereas the market is expected to witness growth at a significant